Rhythm Pharmaceuticals (RYTM) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $87.97, +1.45% vs the prior close of $86.71.
- Volume 644.60K shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
RYTM rises 1.5% to $87.97. Closed at $87.97, +1.45% vs the prior close of $86.71. Day range $87.61–$90.42, opened at $88.41.
RYTM daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — RYTM rises 1.5% to $87.97
- Closed at $87.97, +1.45% vs the prior close of $86.71. Day range $87.61–$90.42, opened at $88.41.
- Volume was 644.60K shares, 1.0x its 50-day average of 666.36K.
- Price is -14.2% vs its 50-day average ($102.53) and -10.1% vs its 200-day average ($97.86).
- 52-week range $74.50–$122.20; today's close sits at 28% of that range, 28.0% below the 52-week high.
Oct 14, 2026 — RYTM ends flat (+0.1%) to $86.71
- Closed at $86.71, +0.12% vs the prior close of $86.61. Day range $85.38–$88.14, opened at $86.41.
- Volume was 585.80K shares, 0.9x its 50-day average of 687.51K.
- Price is -15.8% vs its 50-day average ($102.99) and -11.5% vs its 200-day average ($97.98).
- 52-week range $74.50–$122.20; today's close sits at 26% of that range, 29.0% below the 52-week high.
Oct 13, 2026 — RYTM slides 3.6% to $86.61, a 3-month low
- Closed at $86.61, -3.57% vs the prior close of $89.82. Day range $86.35–$90.50, opened at $89.63.
- Volume was 623.00K shares, 0.9x its 50-day average of 694.34K.
- Price is -16.2% vs its 50-day average ($103.37) and -11.7% vs its 200-day average ($98.10).
- 52-week range $74.50–$122.20; today's close sits at 25% of that range, 29.1% below the 52-week high.
Oct 12, 2026 — RYTM dips 1.1% to $89.82
- Closed at $89.82, -1.06% vs the prior close of $90.78. Day range $89.49–$91.42, opened at $91.05.
- Volume was 543.80K shares, 0.8x its 50-day average of 692.90K.
- Price is -13.4% vs its 50-day average ($103.69) and -8.6% vs its 200-day average ($98.23).
- 52-week range $74.50–$122.20; today's close sits at 32% of that range, 26.5% below the 52-week high.
Oct 9, 2026 — RYTM rises 1.3% to $90.78 on 2.1x normal volume
- Closed at $90.78, +1.27% vs the prior close of $89.64. Day range $89.41–$93.35, opened at $89.67.
- Volume was 1.41M shares, 2.1x its 50-day average of 675.36K — unusually heavy trading.
- Price is -12.6% vs its 50-day average ($103.88) and -7.7% vs its 200-day average ($98.34).
- 52-week range $74.50–$122.20; today's close sits at 34% of that range, 25.7% below the 52-week high.
Oct 8, 2026 — RYTM rises 1.3% to $89.64
- Closed at $89.64, +1.35% vs the prior close of $88.45. Day range $87.01–$90.94, opened at $89.05.
- Volume was 1.01M shares, 1.5x its 50-day average of 665.24K.
- Price is -14.0% vs its 50-day average ($104.18) and -9.0% vs its 200-day average ($98.45).
- 52-week range $74.50–$122.20; today's close sits at 32% of that range, 26.6% below the 52-week high.
Oct 7, 2026 — RYTM dips 2.6% to $88.45, a 3-month low, 8 down days in a row
- Closed at $88.45, -2.56% vs the prior close of $90.77. Day range $88.23–$91.37, opened at $90.77.
- Volume was 939.40K shares, 1.4x its 50-day average of 669.40K.
- Price is -15.4% vs its 50-day average ($104.52) and -10.3% vs its 200-day average ($98.56).
- 52-week range $74.50–$122.20; today's close sits at 29% of that range, 27.6% below the 52-week high.
- That makes 8 straight losses.
Oct 6, 2026 — RYTM dips 1.8% to $90.77, a 3-month low, 7 down days in a row
- Closed at $90.77, -1.82% vs the prior close of $92.45. Day range $90.07–$94.47, opened at $92.55.
- Volume was 992.90K shares, 1.5x its 50-day average of 664.09K.
- Price is -13.5% vs its 50-day average ($104.91) and -8.0% vs its 200-day average ($98.68).
- 52-week range $74.50–$122.20; today's close sits at 34% of that range, 25.7% below the 52-week high.
- That makes 7 straight losses.
Oct 5, 2026 — RYTM dips 0.4% to $92.45, a 3-month low, 6 down days in a row
- Closed at $92.45, -0.41% vs the prior close of $92.83. Day range $89.53–$94.41, opened at $93.95.
- Volume was 1.03M shares, 1.6x its 50-day average of 652.89K.
- Price is -12.1% vs its 50-day average ($105.22) and -6.4% vs its 200-day average ($98.79).
- 52-week range $74.50–$122.20; today's close sits at 38% of that range, 24.3% below the 52-week high.
- That makes 6 straight losses.
Oct 2, 2026 — RYTM dips 0.6% to $92.83, a 3-month low, 5 down days in a row
- Closed at $92.83, -0.62% vs the prior close of $93.41. Day range $92.66–$95.32, opened at $94.97.
- Volume was 503.50K shares, 0.8x its 50-day average of 652.23K.
- Price is -11.9% vs its 50-day average ($105.41) and -6.1% vs its 200-day average ($98.89).
- 52-week range $74.50–$122.20; today's close sits at 38% of that range, 24.0% below the 52-week high.
- That makes 5 straight losses.
RYTM latest news & SEC filings
Every SEC filing by or about RYTM in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Meeker David P sold 2,300 shares at $105.19 (≈$241.94K) on Sep 14, 2026
- Meeker David P sold 6,439 shares at $101.75 (≈$655.17K) on Sep 14, 2026
- Meeker David P sold 30,746 shares at $102.35 (≈$3.15M) on Sep 14, 2026
- Meeker David P sold 8,698 shares at $103.43 (≈$899.63K) on Sep 14, 2026
- Meeker David P sold 1,817 shares at $104.55 (≈$189.97K) on Sep 14, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 14, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Smith Hunter C sold 11,514 shares at $105.37 (≈$1.21M) on Aug 31, 2026
- Smith Hunter C sold 23,072 shares at $104.59 (≈$2.41M) on Aug 31, 2026
- Smith Hunter C sold 28,188 shares at $106.20 (≈$2.99M) on Aug 31, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 31, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 18, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 4, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $71.25M (prior year $48.50M) (+46.9% vs Jun 30, 2025)
- Net income: -$49.30M (prior year -$46.63M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.73 (prior year -$0.75) (loss narrowed vs Jun 30, 2025)
Aug 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
This is a results-day filing: the earnings press release is attached as an exhibit.
Jun 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade RYTM
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Feb 26, 2026, Jan 9, 2026. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.20% (largest 3.6%).
- Liquidity: about 805.30K shares (≈$70.84M) trade per day on average.
- 52-week position: $87.97 vs a range of $74.50–$122.20 (28% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: David P Meeker sold 2,300 shares on Sep 14, 2026.
- Latest filings: 10-Q Aug 4, 2026; 8-K Aug 4, 2026; 8-K Jun 25, 2026.
- Share count: 68.85M shares outstanding (Aug 1, 2026), +3.7% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
RYTM market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 88.41 | 90.42 | 87.61 | 87.97 | 644.60K |
| Oct 14, 2026 | 86.41 | 88.14 | 85.38 | 86.71 | 585.80K |
| Oct 13, 2026 | 89.63 | 90.50 | 86.35 | 86.61 | 623.00K |
| Oct 12, 2026 | 91.05 | 91.42 | 89.49 | 89.82 | 543.80K |
| Oct 9, 2026 | 89.67 | 93.35 | 89.41 | 90.78 | 1.41M |
| Oct 8, 2026 | 89.05 | 90.94 | 87.01 | 89.64 | 1.01M |
| Oct 7, 2026 | 90.77 | 91.37 | 88.23 | 88.45 | 939.40K |
| Oct 6, 2026 | 92.55 | 94.47 | 90.07 | 90.77 | 992.90K |
| Oct 5, 2026 | 93.95 | 94.41 | 89.53 | 92.45 | 1.03M |
| Oct 2, 2026 | 94.97 | 95.32 | 92.66 | 92.83 | 503.50K |
| Oct 1, 2026 | 95.34 | 96.48 | 93.00 | 93.41 | 850.60K |
| Sep 30, 2026 | 96.67 | 97.37 | 95.10 | 95.21 | 737.20K |
| Sep 29, 2026 | 97.92 | 98.91 | 94.51 | 95.71 | 810.90K |
| Sep 28, 2026 | 98.01 | 99.15 | 95.27 | 98.56 | 897.40K |
| Sep 25, 2026 | 98.41 | 99.44 | 96.35 | 98.66 | 864.30K |
| Sep 24, 2026 | 97.73 | 99.28 | 95.38 | 98.31 | 730.80K |
| Sep 23, 2026 | 99.27 | 100.02 | 96.47 | 98.24 | 696.40K |
| Sep 22, 2026 | 100.44 | 101.85 | 98.69 | 99.27 | 499.90K |
| Sep 21, 2026 | 98.47 | 100.76 | 97.54 | 98.83 | 613.60K |
| Sep 18, 2026 | 99.36 | 99.36 | 96.88 | 97.71 | 1.12M |
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals (RYTM) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BOSTON, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1649904.
RYTM board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Stuart A Arbuckle | Director | Jun 25, 2026 |
| Jennifer L Good | Director | Jun 25, 2026 |
| Christophe Jean | Director | Jun 25, 2026 |
| David W J Mcgirr | Director | Jun 25, 2026 |
| Edward T Mathers | Director | Mar 16, 2026 |
| David P Meeker | President and CEO | Sep 14, 2026 |
| Kimberly J Popovits | Director | Apr 3, 2026 |
| Lynn A. Tetrault | Director | Jun 25, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Pamela J. Cramer | Chief Human Resources Officer | Feb 13, 2026 |
| Alastair Garfield | Chief Scientific Officer | Aug 17, 2026 |
| Christopher Paul German | Corporate Controller & CAO | May 19, 2026 |
| Manher Joshi | Chief Medical Officer | Aug 18, 2026 |
| Jennifer Kayden Lee | EVP, Head of North America | Aug 14, 2026 |
| Yann Mazabraud | EVP, Head of International | Aug 14, 2026 |
| David P Meeker | President and CEO | Sep 14, 2026 |
| Joseph Shulman | Chief Technical Officer | Aug 17, 2026 |
| Hunter C Smith | Chief Financial Officer | Sep 1, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 14, 2026 | David P Meeker | Sale | 2,300 | $105.19 |
| Sep 14, 2026 | David P Meeker | Sale | 6,439 | $101.75 |
| Sep 14, 2026 | David P Meeker | Sale | 30,746 | $102.35 |
| Sep 14, 2026 | David P Meeker | Sale | 8,698 | $103.43 |
| Sep 14, 2026 | David P Meeker | Sale | 1,817 | $104.55 |
| Aug 31, 2026 | Hunter C Smith | Sale | 11,514 | $105.37 |
| Aug 31, 2026 | Hunter C Smith | Sale | 23,072 | $104.59 |
| Aug 31, 2026 | Hunter C Smith | Sale | 28,188 | $106.20 |
| Aug 13, 2026 | Joseph Shulman | Sale | 5,079 | $119.75 |
| Aug 13, 2026 | Alastair Garfield | Sale | 1,556 | $117.08 |
| Aug 13, 2026 | Alastair Garfield | Sale | 800 | $119.17 |
| Aug 13, 2026 | Alastair Garfield | Sale | 2,007 | $116.11 |
| Aug 13, 2026 | Alastair Garfield | Sale | 3,400 | $118.28 |
| Aug 13, 2026 | Jennifer Kayden Lee | Sale | 75,834 | $117.38 |
| Aug 12, 2026 | Yann Mazabraud | Sale | 14,568 | $115.43 |
RYTM financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $189.76M | $-196.54M | -3.11 | $-115.67M |
| Dec 31, 2024 | $130.13M | $-260.60M | -4.34 | $-113.88M |
| Dec 31, 2023 | $77.43M | $-184.68M | -3.20 | $-136.16M |
| Dec 31, 2022 | $23.64M | $-181.12M | -3.47 | $-173.43M |
| Dec 31, 2021 | $3.15M | $-69.61M | -1.40 | $-146.00M |
Latest balance sheet: total assets $437.27M, total liabilities $219.97M, cash $65.61M (as of Jun 30, 2026).
RYTM earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $105.78 |
| May 5, 2026 | 8-K Item 2.02 (results) | $92.31 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $98.07 |
| Jan 9, 2026 | 8-K Item 2.02 (results) | $101.02 |
| Nov 4, 2025 | 8-K Item 2.02 (results) | $104.99 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $88.57 |
| May 7, 2025 | 8-K Item 2.02 (results) | $64.63 |
| Feb 26, 2025 | 8-K Item 2.02 (results) | $53.32 |
| Jan 10, 2025 | 8-K Item 2.02 (results) | $56.17 |
| Nov 5, 2024 | 8-K Item 2.02 (results) | $56.25 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on RYTM
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.